- |||||||||| Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial primary completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Nov 28, 2017 P=N/A, N=134, Recruiting, Together our results suggest that stimulation of NO generation from constitutive synthases may be primarily responsible for the reported antihyperplastic and NK cell-preserving effects of the β-blockers, and that similar effects may be observed in other immunity normalizing compounds that also promote endothelial NO synthesis. Trial primary completion date: Jun 2018 --> Dec 2018
- |||||||||| Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial primary completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Mar 8, 2017 P=N/A, N=134, Recruiting, Trial primary completion date: Jun 2018 --> Dec 2018 Trial primary completion date: Mar 2017 --> Jun 2018
- |||||||||| Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial primary completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Sep 6, 2016 P=N/A, N=134, Recruiting, Trial primary completion date: Mar 2017 --> Jun 2018 Trial primary completion date: Aug 2016 --> Mar 2017
- |||||||||| Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial primary completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Sep 24, 2015 P=N/A, N=134, Recruiting, Trial primary completion date: Aug 2016 --> Mar 2017 Trial primary completion date: Aug 2015 --> Aug 2016
- |||||||||| Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Enrollment change: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Jun 11, 2015 P=N/A, N=134, Recruiting, Trial primary completion date: Aug 2015 --> Aug 2016 N=50 --> 134
- |||||||||| Visken (pindolol) / Novartis
Enrollment change, Trial termination, Trial primary completion date: ESPION: EScitalopram PIndolol ONset of Action (clinicaltrials.gov) - May 27, 2015 P2/3, N=18, Terminated, N=50 --> 134 N=135 --> 18 | Recruiting --> Terminated | Trial primary completion date: Oct 2013 --> Apr 2013; Recruitment difficulties
|